VIRGINIA RETIREMENT SYSTEMS ET Al Invests $1.54 Million in Supernus Pharmaceuticals, Inc. $SUPN

VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 48,736 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,536,000.

Several other large investors have also added to or reduced their stakes in SUPN. Armistice Capital LLC increased its stake in Supernus Pharmaceuticals by 7.4% in the 1st quarter. Armistice Capital LLC now owns 5,196,000 shares of the specialty pharmaceutical company’s stock valued at $170,169,000 after buying an additional 360,000 shares during the last quarter. GW&K Investment Management LLC grew its holdings in shares of Supernus Pharmaceuticals by 14.6% in the 1st quarter. GW&K Investment Management LLC now owns 1,382,441 shares of the specialty pharmaceutical company’s stock valued at $45,275,000 after acquiring an additional 176,091 shares in the last quarter. Nuveen LLC acquired a new stake in shares of Supernus Pharmaceuticals in the first quarter valued at about $4,393,000. Millennium Management LLC raised its holdings in Supernus Pharmaceuticals by 370.5% during the first quarter. Millennium Management LLC now owns 143,356 shares of the specialty pharmaceutical company’s stock worth $4,695,000 after acquiring an additional 112,886 shares in the last quarter. Finally, Jane Street Group LLC bought a new stake in Supernus Pharmaceuticals during the first quarter worth about $3,641,000.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on SUPN shares. Zacks Research raised Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, September 17th. Cantor Fitzgerald boosted their target price on shares of Supernus Pharmaceuticals from $46.00 to $63.00 and gave the stock an “overweight” rating in a report on Tuesday, September 30th. Wall Street Zen lowered shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, October 3rd. Weiss Ratings reissued a “hold (c)” rating on shares of Supernus Pharmaceuticals in a research report on Wednesday, October 8th. Finally, Piper Sandler upgraded shares of Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and boosted their price objective for the stock from $40.00 to $65.00 in a research note on Thursday, October 9th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $64.00.

Supernus Pharmaceuticals Stock Performance

NASDAQ SUPN opened at $50.67 on Thursday. The stock has a market cap of $2.84 billion, a PE ratio of 44.06 and a beta of 0.78. The firm has a 50-day moving average of $46.47 and a 200-day moving average of $37.63. Supernus Pharmaceuticals, Inc. has a 52-week low of $29.16 and a 52-week high of $52.15.

Insider Buying and Selling

In related news, CFO Timothy C. Dec sold 11,780 shares of Supernus Pharmaceuticals stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $44.49, for a total transaction of $524,092.20. Following the completion of the sale, the chief financial officer owned 1,246 shares of the company’s stock, valued at approximately $55,434.54. The trade was a 90.43% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Frank Mottola sold 5,000 shares of Supernus Pharmaceuticals stock in a transaction dated Friday, September 12th. The stock was sold at an average price of $45.87, for a total transaction of $229,350.00. Following the sale, the senior vice president directly owned 15,496 shares of the company’s stock, valued at $710,801.52. The trade was a 24.40% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 362,741 shares of company stock valued at $16,390,592. Company insiders own 8.80% of the company’s stock.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.